This notion arises the possibility that KRAS-LKB1 (KL) mutant cancer are refractory to immunotherapy rather because they usually preserve unaltered expression of TP53 than because of intrinsic LKB1-dependant mechanisms. This evidence concerns the gene KRAS and cancer.